TY - JOUR AU - Bocsik, Alexandra AU - Gróf, Ilona AU - Kiss, Lóránd AU - Ötvös, Ferenc AU - Zsíros, Ottó AU - Daruka, Lejla AU - Fülöp, Lívia AU - Vastag, Monika AU - Kittel, Ágnes AU - Imre, Norbert AU - Martinek, Tamás AU - Pál, Csaba AU - Révész, Piroska AU - Deli, Mária Anna TI - Dual Action of the PN159/KLAL/MAP Peptide. Increase of Drug Penetration across Caco-2 Intestinal Barrier Model by Modulation of Tight Junctions and Plasma Membrane Permeability. TS - Increase of Drug Penetration across Caco-2 Intestinal Barrier Model by Modulation of Tight Junctions and Plasma Membrane Permeability. JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 11 PY - 2019 IS - 2 PG - 21 SN - 1999-4923 DO - 10.3390/pharmaceutics11020073 UR - https://m2.mtmt.hu/api/publication/30434125 ID - 30434125 AB - The absorption of drugs is limited by the epithelial barriers of the gastrointestinal tract. One of the strategies to improve drug delivery is the modulation of barrier function by the targeted opening of epithelial tight junctions. In our previous study the 18-mer amphiphilic PN159 peptide was found to be an effective tight junction modulator on intestinal epithelial and blood⁻brain barrier models. PN159, also known as KLAL or MAP, was described to interact with biological membranes as a cell-penetrating peptide. In the present work we demonstrated that the PN159 peptide as a penetration enhancer has a dual action on intestinal epithelial cells. The peptide safely and reversibly enhanced the permeability of Caco-2 monolayers by opening the intercellular junctions. The penetration of dextran molecules with different size and four efflux pump substrate drugs was increased several folds. We identified claudin-4 and -7 junctional proteins by docking studies as potential binding partners and targets of PN159 in the opening of the paracellular pathway. In addition to the tight junction modulator action, the peptide showed cell membrane permeabilizing and antimicrobial effects. This dual action is not general for cell-penetrating peptides (CPPs), since the other three CPPs tested did not show barrier opening effects. LA - English DB - MTMT ER - TY - JOUR AU - Ismail, Ruba AU - Sovány, Tamás AU - Gácsi, Attila AU - Ambrus, Rita AU - Katona, Gábor AU - Imre, Norbert AU - Pannonhalminé Csóka, Ildikó TI - Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery JF - PHARMACEUTICAL RESEARCH J2 - PHAR RES VL - 36 PY - 2019 IS - 7 PG - 16 SN - 0724-8741 DO - 10.1007/s11095-019-2620-9 UR - https://m2.mtmt.hu/api/publication/30679490 ID - 30679490 N1 - University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Szeged, H-6720, Hungary University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Analysis, Somogyi u. 4, Szeged, H-6720, Hungary Export Date: 15 November 2019 CODEN: PHREE Correspondence Address: Csóka, I.; University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Hungary; email: csoka@pharm.u-szeged.hu Chemicals/CAS: chlormethine, 51-75-2, 55-86-7, 82905-71-3; liraglutide, 204656-20-2; polyglactin, 26780-50-7, 34346-01-5; Drug Carriers; Emulsions; Hypoglycemic Agents; Liraglutide; Polylactic Acid-Polyglycolic Acid Copolymer Manufacturers: xi an health, China Funding details: EFOP-3.6.1-16-2016-00008 Funding text 1: This research was supported by the EU-funded Hungarian grant EFOP-3.6.1-16-2016-00008. University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Szeged, H-6720, Hungary University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Analysis, Somogyi u. 4, Szeged, H-6720, Hungary Cited By :1 Export Date: 22 November 2019 CODEN: PHREE Correspondence Address: Csóka, I.; University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Hungary; email: csoka@pharm.u-szeged.hu Chemicals/CAS: chlormethine, 51-75-2, 55-86-7, 82905-71-3; liraglutide, 204656-20-2; polyglactin, 26780-50-7, 34346-01-5; Drug Carriers; Emulsions; Hypoglycemic Agents; Liraglutide; Polylactic Acid-Polyglycolic Acid Copolymer Manufacturers: xi an health, China Funding details: EFOP-3.6.1-16-2016-00008 Funding text 1: This research was supported by the EU-funded Hungarian grant EFOP-3.6.1-16-2016-00008. University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Szeged, H-6720, Hungary University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Analysis, Somogyi u. 4, Szeged, H-6720, Hungary Cited By :1 Export Date: 23 November 2019 CODEN: PHREE Correspondence Address: Csóka, I.; University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Hungary; email: csoka@pharm.u-szeged.hu Chemicals/CAS: chlormethine, 51-75-2, 55-86-7, 82905-71-3; liraglutide, 204656-20-2; polyglactin, 26780-50-7, 34346-01-5; Drug Carriers; Emulsions; Hypoglycemic Agents; Liraglutide; Polylactic Acid-Polyglycolic Acid Copolymer Manufacturers: xi an health, China Funding details: EFOP-3.6.1-16-2016-00008 Funding text 1: This research was supported by the EU-funded Hungarian grant EFOP-3.6.1-16-2016-00008. LA - English DB - MTMT ER - TY - JOUR AU - Pallagi, Edina AU - Ismail, Ruba AU - Paál, Tamás AU - Pannonhalminé Csóka, Ildikó TI - Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development JF - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES J2 - EUR J PHARM SCI VL - 122 PY - 2018 SP - 160 EP - 169 PG - 10 SN - 0928-0987 DO - 10.1016/j.ejps.2018.07.003 UR - https://m2.mtmt.hu/api/publication/3393606 ID - 3393606 N1 - #hozzárendelt szerző ismeretlen Cited By :4 Export Date: 15 November 2019 CODEN: EPSCE Correspondence Address: Pallagi, E.; University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Hungary; email: edina.pallagi@pharm.u-szeged.hu Chemicals/CAS: glucagon like peptide 1, 89750-14-1; liraglutide, 204656-20-2; polyglactin, 26780-50-7, 34346-01-5; Hypoglycemic Agents; Liraglutide; Peptides; Polymers Manufacturers: xian health biochem technology, China Funding details: Great Ormond Street Institute of Child Health Funding text 1: API Active Pharmaceutical Ingredient CMAs Critical Material Attributes CPPs Critical Process Parameters CQAs Critical Quality Attributes DL Drug loading DoE Design of Experiments DS Design Space EE Encapsulation Efficiency EMA European Medicine Agency FDA Food and Drug Administration GLP-1 glucagon like peptide −1 ICH International Council of Harmonisation Lira Liraglutide NPs Nanoparticles PDI Polydispersity Index PLGA NPs Poly lactic- co -glycolic acid -nanoparticles PLGA Poly lactic- co -glycolic acid QbD Quality by Design QTPP Quality Target Product Profile RA Risk Assessment Cited By :5 Export Date: 18 November 2019 CODEN: EPSCE Correspondence Address: Pallagi, E.; University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Hungary; email: edina.pallagi@pharm.u-szeged.hu Chemicals/CAS: glucagon like peptide 1, 89750-14-1; liraglutide, 204656-20-2; polyglactin, 26780-50-7, 34346-01-5; Hypoglycemic Agents; Liraglutide; Peptides; Polymers Manufacturers: xian health biochem technology, China Funding details: Great Ormond Street Institute of Child Health Funding text 1: API Active Pharmaceutical Ingredient CMAs Critical Material Attributes CPPs Critical Process Parameters CQAs Critical Quality Attributes DL Drug loading DoE Design of Experiments DS Design Space EE Encapsulation Efficiency EMA European Medicine Agency FDA Food and Drug Administration GLP-1 glucagon like peptide −1 ICH International Council of Harmonisation Lira Liraglutide NPs Nanoparticles PDI Polydispersity Index PLGA NPs Poly lactic- co -glycolic acid -nanoparticles PLGA Poly lactic- co -glycolic acid QbD Quality by Design QTPP Quality Target Product Profile RA Risk Assessment Cited By :5 Export Date: 21 November 2019 CODEN: EPSCE Correspondence Address: Pallagi, E.; University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6, Hungary; email: edina.pallagi@pharm.u-szeged.hu Chemicals/CAS: glucagon like peptide 1, 89750-14-1; liraglutide, 204656-20-2; polyglactin, 26780-50-7, 34346-01-5; Hypoglycemic Agents; Liraglutide; Peptides; Polymers Manufacturers: xian health biochem technology, China Funding details: Great Ormond Street Institute of Child Health Funding text 1: API Active Pharmaceutical Ingredient CMAs Critical Material Attributes CPPs Critical Process Parameters CQAs Critical Quality Attributes DL Drug loading DoE Design of Experiments DS Design Space EE Encapsulation Efficiency EMA European Medicine Agency FDA Food and Drug Administration GLP-1 glucagon like peptide −1 ICH International Council of Harmonisation Lira Liraglutide NPs Nanoparticles PDI Polydispersity Index PLGA NPs Poly lactic- co -glycolic acid -nanoparticles PLGA Poly lactic- co -glycolic acid QbD Quality by Design QTPP Quality Target Product Profile RA Risk Assessment LA - English DB - MTMT ER - TY - JOUR AU - Ismail, Ruba AU - Pannonhalminé Csóka, Ildikó TI - Novel strategies in the oral delivery of antidiabetic peptide drugs – Insulin, GLP 1 and its analogs JF - EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS J2 - EUR J PHARM BIOPHARM VL - 115 PY - 2017 SP - 257 EP - 267 PG - 11 SN - 0939-6411 DO - 10.1016/j.ejpb.2017.03.015 UR - https://m2.mtmt.hu/api/publication/3294216 ID - 3294216 N1 - Cited By :24 Export Date: 15 November 2019 CODEN: EJPBE Correspondence Address: Ismail, R.Eötvös u. 6, Hungary; email: ismailruba89@gmail.com Chemicals/CAS: glucagon like peptide 1, 89750-14-1; insulin, 9004-10-8; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Peptides Cited By :25 Export Date: 18 November 2019 CODEN: EJPBE Correspondence Address: Ismail, R.Eötvös u. 6, Hungary; email: ismailruba89@gmail.com Chemicals/CAS: glucagon like peptide 1, 89750-14-1; insulin, 9004-10-8; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Peptides Cited By :25 Export Date: 21 November 2019 CODEN: EJPBE Correspondence Address: Ismail, R.Eötvös u. 6, Hungary; email: ismailruba89@gmail.com Chemicals/CAS: glucagon like peptide 1, 89750-14-1; insulin, 9004-10-8; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Peptides LA - English DB - MTMT ER - TY - JOUR AU - Bocsik, Alexandra AU - Walter, Fruzsina AU - Gyebrovszki, A AU - Fülöp, Lívia AU - Blasig, IE AU - Dabrowski, S AU - Ötvös, Ferenc AU - Tóth, András AU - Rákhely, Gábor AU - Veszelka, Szilvia AU - Vastag, M AU - Révész, Piroska AU - Deli, Mária Anna TI - Reversible opening of intercellular junctions of intestinal epithelial and brain endothelial cells with tight junction modulator peptides JF - JOURNAL OF PHARMACEUTICAL SCIENCES J2 - J PHARM SCI VL - 105 PY - 2016 IS - 2 SP - 754 EP - 765 PG - 12 SN - 0022-3549 DO - 10.1016/j.xphs.2015.11.018 UR - https://m2.mtmt.hu/api/publication/3009615 ID - 3009615 LA - English DB - MTMT ER - TY - JOUR AU - Kiss, Lóránd AU - Virághné Hellinger, Éva AU - Pilbat, Ana Maria AU - Kittel, Ágnes AU - Török, Zsolt AU - Füredi, András AU - Szakács, Gergely AU - Veszelka, Szilvia AU - Sipos, Péter AU - Ózsvári, B AU - Puskás, László AU - Vastag, M AU - Révész, Piroska AU - Deli, Mária Anna TI - Sucrose esters increase drug penetration, but do not inhibit P-glycoprotein in Caco-2 intestinal epithelial cells JF - JOURNAL OF PHARMACEUTICAL SCIENCES J2 - J PHARM SCI VL - 103 PY - 2014 IS - 10 SP - 3107 EP - 3119 PG - 13 SN - 0022-3549 DO - 10.1002/jps.24085 UR - https://m2.mtmt.hu/api/publication/2709800 ID - 2709800 AB - Sucrose fatty acid esters are increasingly used as excipients in pharmaceutical products, but few data are available on their toxicity profile, mode of action, and efficacy on intestinal epithelial models. Three water-soluble sucrose esters, palmitate (P-1695), myristate (M-1695), laurate (D-1216), and two reference absorption enhancers, Tween 80 and Cremophor RH40, were tested on Caco-2 cells. Caco-2 monolayers formed a good barrier as reflected by high transepithelial resistance and positive immunostaining for junctional proteins claudin-1, ZO-1, and -catenin. Sucrose esters in nontoxic concentrations significantly reduced resistance and impedance, and increased permeability for atenolol, fluorescein, vinblastine, and rhodamine 123 in Caco-2 monolayers. No visible opening of the tight junctions was induced by sucrose esters assessed by immunohistochemistry and electron microscopy, but some alterations were seen in the structure of filamentous actin microfilaments. Sucrose esters fluidized the plasma membrane and enhanced the accumulation of efflux transporter ligands rhodamine 123 and calcein AM in epithelial cells, but did not inhibit the P-glycoprotein (P- gp)-mediated calcein AM accumulation in MES-SA/Dx5 cell line. These data indicate that in addition to their dissolution-increasing properties sucrose esters can enhance drug permeability through both the transcellular and paracellular routes without inhibiting P- LA - English DB - MTMT ER - TY - JOUR AU - Kiss, Lóránd AU - Walter, Fruzsina AU - Bocsik, Alexandra AU - Veszelka, Szilvia AU - Ózsvári, B AU - Puskás, László AU - Révész, Piroska AU - Deli, Mária Anna TI - Kinetic Analysis of the Toxicity of Pharmaceutical Excipients Cremophor EL and RH40 on Endothelial and Epithelial Cells JF - JOURNAL OF PHARMACEUTICAL SCIENCES J2 - J PHARM SCI VL - 102 PY - 2013 IS - 4 SP - 1173 EP - 1181 PG - 9 SN - 0022-3549 DO - 10.1002/jps.23458 UR - https://m2.mtmt.hu/api/publication/2153338 ID - 2153338 N1 - Cited By :78 Export Date: 20 June 2022 CODEN: JPMSA LA - English DB - MTMT ER - TY - JOUR AU - Virághné Hellinger, Éva AU - Veszelka, Szilvia AU - Tóth, Andrea AU - Walter, Fruzsina AU - Kittel, Ágnes AU - Bakk, ML AU - Tihanyi, Károly AU - Háda, Viktor AU - Nakagawa, S AU - Thuy, DH AU - Niwa, M AU - Deli, Mária Anna AU - Vastag, M TI - Comparison of brain capillary endothelial cell based and epithelial cell based (MDCK-MDR1, Caco-2, and VB-Caco-2) surrogate blood-brain barrier penetration models JF - EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS J2 - EUR J PHARM BIOPHARM VL - 82 PY - 2012 IS - 2 SP - 340 EP - 351 PG - 12 SN - 0939-6411 DO - 10.1016/j.ejpb.2012.07.020 UR - https://m2.mtmt.hu/api/publication/2034983 ID - 2034983 N1 - Division of Pharmacology and Drug Safety Research, Gedeon Richter Plc., Gyömri út. 19-21, H-1103 Budapest, Hungary Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary Spectroscopic Research, Gedeon Richter Plc., Budapest, Hungary Department of Pharmacology 1, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan BBB Laboratory, PharmaCo-Cell Co. Ltd., Nagasaki, Japan Cited By :108 Export Date: 1 June 2020 CODEN: EJPBE Correspondence Address: Vastag, M.; Division of Pharmacology and Drug Safety Research, Gedeon Richter Plc., Gyömri út. 19-21, H-1103 Budapest, Hungary; email: m.vastag@richter.hu Chemicals/CAS: aldosterone, 52-39-1, 6251-69-0; atenolol, 29122-68-7, 93379-54-5; caffeine, 58-08-2; chlorothiazide, 58-94-6, 7085-44-1; cimetidine, 51481-61-9, 70059-30-2; colchicine, 64-86-8; corticosterone, 50-22-6; dexamethasone, 50-02-2; digoxin, 20830-75-5, 57285-89-9; estradiol, 50-28-2; furosemide, 54-31-9; hydrocortisone, 50-23-7; indometacin, 53-86-1, 74252-25-8, 7681-54-1; ketoconazole, 65277-42-1; lidocaine, 137-58-6, 24847-67-4, 56934-02-2, 73-78-9; loperamide, 34552-83-5, 53179-11-6; metoprolol, 37350-58-6; multidrug resistance protein, 149200-37-3, 208997-77-7; omeprazole, 73590-58-6, 95510-70-6; paracetamol, 103-90-2; phenazone, 60-80-0; phenytoin, 57-41-0, 630-93-3; progesterone, 57-83-0; propranolol, 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; quinidine, 56-54-2; ranitidine, 66357-35-5, 66357-59-3; salicylic acid, 63-36-5, 69-72-7; theobromine, 83-67-0; verapamil, 152-11-4, 52-53-9; vinblastine, 865-21-4; P-Glycoprotein LA - English DB - MTMT ER - TY - JOUR AU - Kürti, Levente AU - Veszelka, Szilvia AU - Bocsik, Alexandra AU - Dung, Ngo Thi Khue AU - Ozsvari, B AU - Puskás, László AU - Kittel, Ágnes AU - Révész, Piroska AU - Deli, Mária Anna TI - The effect of sucrose esters on a culture model of the nasal barrier JF - TOXICOLOGY IN VITRO J2 - TOXICOL IN VITRO VL - 26 PY - 2012 IS - 3 SP - 445 EP - 454 PG - 10 SN - 0887-2333 DO - 10.1016/j.tiv.2012.01.015 UR - https://m2.mtmt.hu/api/publication/1847178 ID - 1847178 N1 - Funding Agency and Grant Number: European UnionEuropean Union (EU) [TAMOP-4.2.1/B-09/1/KONV-2010-0005]; European Regional Development FundEuropean Union (EU) Funding text: The Project named "TAMOP-4.2.1/B-09/1/KONV-2010-0005 - Creating the Centre of Excellence at the University of Szeged" is supported by the European Union and co-financed by the European Regional Development Fund. Laboratory of Molecular Neurobiology, Institute of Biophysics, Biological Research Centre of the Hungarian Academy of Sciences, Temesvári Krt. 62, H-6726 Szeged, Hungary Department of Pharmaceutical Technology, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary Avidin Ltd., Közép fasor 52, H-6726 Szeged, Hungary Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u. 43, H-1083 Budapest, Hungary Cited By :39 Export Date: 9 October 2020 CODEN: TIVIE Correspondence Address: Deli, M.A.; Laboratory of Molecular Neurobiology, Institute of Biophysics, Biological Research Centre of the Hungarian Academy of Sciences, Temesvári Krt. 62, H-6726 Szeged, Hungary; email: deli@brc.hu Chemicals/CAS: cremophor, 39279-69-1, 51142-51-9; polysorbate 80, 8050-83-7, 9005-65-6; sucrose laurate, 25339-99-5; Dextrans, 9004-54-0; Excipients; Fluorescein-5-isothiocyanate, 3326-32-7; L-Lactate Dehydrogenase, 1.1.1.27; Polyethylene Glycols; Polysorbates; Sucrose, 57-50-1; cremophor, 39279-69-1; fluorescein isothiocyanate dextran; sucrose monolaurate, 25339-99-5; sucrose myristate, 9042-71-1 Funding details: European Commission, EC Funding details: European Regional Development Fund, FEDER Funding text 1: The Project named “TÁMOP-4.2.1/B-09/1/KONV-2010-0005 – Creating the Centre of Excellence at the University of Szeged” is supported by the European Union and co-financed by the European Regional Development Fund. AB - Sucrose esters are effective solubilizers and there is an interest to use them as pharmaceutical excipients for nasal dru1 delivery. We have determined for the first time the non-toxic doses of laurate and myristate sucrose esters by four independent methods, and their effects on epithelial permeability using RPMI 2650 human nasal epithelial cell line. Based on real-time cell electronic sensing, MTT dye conversion and lactate dehydrogenase release methods reference surfactant Cremophor RH40 proved to be the least toxic excipient, and could be used at 5mg/mL concentration for 1h in epithelial cells without cellular damage. The non-toxic dose of Tween 80 was 1mg/mL, while the dose of laurate and myristate sucrose esters that could be safely used on cells for 1h was 0.1mg/mL. Both the reference surfactants and the sucrose esters significantly enhanced the permeability of epithelial cell layers for the paracellular marker FITC-labelled 4.4kDa dextran at 0.1mg/mL concentration. The effects of sucrose esters on epithelial permeability were dose-dependent. These data indicate that laurate and myristate sucrose esters can be potentially used as permeability enhancers in nasal formulations to augment drug delivery to the systemic circulation. LA - English DB - MTMT ER - TY - JOUR AU - Deli, Mária Anna TI - Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery JF - BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES J2 - BBA-BIOMEMBRANES VL - 1788 PY - 2009 IS - 4 SP - 892 EP - 910 PG - 19 SN - 0005-2736 DO - 10.1016/j.bbamem.2008.09.016 UR - https://m2.mtmt.hu/api/publication/1920731 ID - 1920731 N1 - Megjegyzés-20963954 FU: National Office for Research and Technology [RET 08/2004]; Hungarian : Ministry of Health [ETT 589/2006] FX: This work was supported by grants from the National Office for Research : and Technology (RET 08/2004) and the Hungarian Ministry of Health ETT : 589/2006. The help of Dr. Csongor AbrahAm for critical reading of the : manuscript is gratefully acknowledged. Megjegyzés-21456976 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22110013 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22120929 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22171311 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22182274 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22191831 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22193458 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22195546 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-22217622 DI: 10.1016/j.bbamem.2008.09.016 Megjegyzés-20963631 FU: National Office for Research and Technology [RET 08/2004]; Hungarian : Ministry of Health [ETT 589/2006] FX: This work was supported by grants from the National Office for Research : and Technology (RET 08/2004) and the Hungarian Ministry of Health ETT : 589/2006. The help of Dr. Csongor AbrahAm for critical reading of the : manuscript is gratefully acknowledged. Megjegyzés-21461393 Chemicals/CAS: calnexin, 139873-08-8; cyclodextrin, 12619-70-4; occludin, 176304-61-3; uvomorulin, 112956-45-3; Chelating Agents; Cholera Toxin, 9012-63-9; Membrane Proteins; claudin 1; occludin; zonulin LA - English DB - MTMT ER -